13.5. 2013 BioTurku®

Biotie announces start of clinical study with nepicastat in cocaine dependence

Biotie Therapies has announced the start of a Phase 2 clinical study evaluating nepicastat (SYN117) in cocaine dependence. The National Institute on Drug Abuse (NIDA) at the US National Institutes of Health is funding the conduct of the study under an agreement signed in December 2011.

The study is a randomized, double-blind placebo-controlled 11-week trial and is expected to enroll about 180 treatment-seeking cocaine-dependent subjects. The study will be conducted at approximately 12 US clinics specializing in the treatment of drug dependence.

The trial is expected to take approximately two years to complete.